MHRA grants approval for RXC004 trial restart
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has given formal approval for Redx Pharma to re-commence a Phase I/IIa trial of experimental cancer therapy RXC004.
Read More
Tag: Wnt signalling pathway
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
